PubRank

Eldad Melamed

Author PubWeight™ 103.57‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009 5.81
2 VPS35 mutations in Parkinson disease. Am J Hum Genet 2011 4.16
3 Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004 2.90
4 The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013 2.65
5 The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004 2.40
6 Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Mov Disord 2009 1.90
7 Antioxidant therapy in acute central nervous system injury: current state. Pharmacol Rev 2002 1.76
8 Handedness as a predictor of side of onset of Parkinson's disease. Parkinsonism Relat Disord 2008 1.74
9 A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011 1.68
10 Lesions outside the CNS in Parkinson's disease. Mov Disord 2009 1.55
11 The mystery of motor asymmetry in Parkinson's disease. Lancet Neurol 2006 1.55
12 Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Exp Neurol 2006 1.47
13 The "dying-back" phenomenon of motor neurons in ALS. J Mol Neurosci 2010 1.45
14 The hyperperfusion syndrome: an under-recognized complication of carotid endarterectomy. Isr Med Assoc J 2004 1.40
15 Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. J Mol Neurosci 2002 1.25
16 A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008 1.24
17 The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol 2007 1.21
18 Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord 2006 1.20
19 Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection. Invest Ophthalmol Vis Sci 2010 1.18
20 Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells Dev 2006 1.17
21 [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006 1.14
22 Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opin Biol Ther 2009 1.13
23 DJ-1 protects against dopamine toxicity. J Neural Transm (Vienna) 2008 1.11
24 Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology 2008 1.07
25 Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible. Stem Cells 2009 1.07
26 Apoptosis and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003 1.06
27 Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev 2009 1.03
28 Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells Dev 2008 1.01
29 Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends Mol Med 2003 1.00
30 A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem 2004 1.00
31 Mesenchymal stem cells stimulate endogenous neurogenesis in the subventricular zone of adult mice. Stem Cell Rev 2011 0.98
32 Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res 2003 0.98
33 Therapeutic potential of neurotrophic factors in neurodegenerative diseases. BioDrugs 2005 0.97
34 Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD-1 mutant. J Mol Neurosci 2008 0.97
35 Differentiated mesenchymal stem cells for sciatic nerve injury. Stem Cell Rev 2011 0.96
36 Wnt signaling enhances neurogenesis and improves neurological function after focal ischemic injury. PLoS One 2012 0.96
37 Antioxidant treatment in Alzheimer's disease: current state. J Mol Neurosci 2003 0.96
38 Neurogenesis in the aged and neurodegenerative brain. Apoptosis 2010 0.96
39 Anti-semaphorin 3A antibodies rescue retinal ganglion cells from cell death following optic nerve axotomy. J Biol Chem 2002 0.96
40 Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells. Stem Cells Dev 2009 0.95
41 DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS. J Mol Neurosci 2008 0.94
42 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 2004 0.93
43 Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis. J Mol Neurosci 2009 0.93
44 Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. J Mol Neurosci 2004 0.92
45 Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease. J Mol Neurosci 2009 0.92
46 Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS. J Mol Neurosci 2012 0.92
47 Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov Disord 2012 0.91
48 Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging. Stem Cells 2008 0.91
49 A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease. Eur J Neurosci 2005 0.89
50 Docosahexaenoic acid and arachidonic acid are fundamental supplements for the induction of neuronal differentiation. J Lipid Res 2006 0.88
51 Role of DJ-1 in Parkinson's disease. J Mol Neurosci 2006 0.88
52 Novel molecular imaging of cell death in experimental cerebral stroke. Brain Res 2007 0.87
53 Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases. Isr Med Assoc J 2009 0.87
54 The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol 2007 0.86
55 Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neurosci Lett 2006 0.86
56 Dopaminergic differentiation of human mesenchymal stem cells--utilization of bioassay for tyrosine hydroxylase expression. Neurosci Lett 2007 0.86
57 Hemin-induced apoptosis in PC12 and neuroblastoma cells: implications for local neuronal death associated with intracerebral hemorrhage. Neurotox Res 2003 0.85
58 Unilateral lower limb rest tremor is not necessarily a presenting symptom of Parkinson's disease. Mov Disord 2010 0.85
59 Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid β-peptide. J Neurochem 2011 0.85
60 Familial Parkinsonism with digenic parkin and PINK1 mutations. Mov Disord 2008 0.85
61 Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. Curr Pharm Des 2006 0.84
62 Comparative characterization of bone marrow-derived mesenchymal stromal cells from four different rat strains. Cytotherapy 2009 0.84
63 A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia. Clin Neuropharmacol 2005 0.83
64 Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. Front Neurosci 2013 0.83
65 Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease. Mov Disord 2006 0.82
66 Cell replacement therapy for Parkinson's disease: how close are we to the clinic? Expert Rev Neurother 2011 0.82
67 Bent knees and tiptoeing: late manifestations of end-stage Parkinson's disease. Mov Disord 2004 0.82
68 Experimental encephalomyelitis induces changes in DJ-1: implications for oxidative stress in multiple sclerosis. Antioxid Redox Signal 2006 0.81
69 DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging. J Gerontol A Biol Sci Med Sci 2012 0.81
70 Neuroprotection in progressive brain disorders. Isr Med Assoc J 2003 0.81
71 Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias. J Neural Transm (Vienna) 2012 0.81
72 Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application. EPMA J 2010 0.81
73 Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease. PLoS Curr 2012 0.81
74 Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice. Neurosci Lett 2004 0.81
75 New drugs in the future treatment of Parkinson's disease. J Neurol 2002 0.80
76 Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity. J Mol Neurosci 2013 0.80
77 Placental mesenchymal stromal cells induced into neurotrophic factor-producing cells protect neuronal cells from hypoxia and oxidative stress. Cytotherapy 2011 0.80
78 Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease. J Mol Neurosci 2004 0.80
79 Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. Neurol Sci 2009 0.80
80 Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapy. Muscle Nerve 2014 0.79
81 Stem cells treatment for sciatic nerve injury. Expert Opin Biol Ther 2011 0.79
82 The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol Toxicol 2003 0.79
83 Adult stem cells for neuronal repair. Isr Med Assoc J 2006 0.79
84 Respiratory distress: an unrecognized non-motor phenomenon in patients with parkinsonism. J Neural Transm (Vienna) 2011 0.79
85 Taking sides: is handedness involved in motor asymmetry of Parkinson's disease? Mov Disord 2012 0.78
86 The molecular mechanisms of dopamine toxicity. Adv Neurol 2003 0.78
87 Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clin Neuropharmacol 2003 0.78
88 Stem cell grafting in parkinsonism--why, how and when. Parkinsonism Relat Disord 2014 0.78
89 The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007 0.78
90 Induction of neuron-specific enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells. J Mol Neurosci 2003 0.78
91 Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol 2003 0.78
92 Focal dystonia as the presenting sign in Creutzfeldt-Jakob disease. Mov Disord 2002 0.78
93 Harnessing neurogenesis for the possible treatment of Parkinson's disease. J Comp Neurol 2014 0.77
94 Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord 2002 0.77
95 Residual striatal dopaminergic nerve terminals in very long-standing Parkinson's disease: a single photon emission computed tomography imaging study. Mov Disord 2010 0.76
96 Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol Toxicol 2003 0.75
97 Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease. Mov Disord 2006 0.75
98 Role of DJ-1 in parkinson's disease. J Mol Neurosci 2007 0.75
99 [Neurological complications in Down's Syndrome]. Harefuah 2002 0.75
100 Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease. Biomed Pharmacother 2007 0.75
101 Neurocysticercosis. Isr Med Assoc J 2002 0.75
102 Editorial: apoptosis in the aging brain. Apoptosis 2010 0.75
103 123I-FP-CIT SPECT imaging of dopamine transporters in patients with recurrent sudden falls: are such falls a distinct entity? J Nucl Med Technol 2007 0.75
104 Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant. J Mol Neurosci 2005 0.75
105 Preface. Handb Clin Neurol 2007 0.75
106 Successful treatment of truncal myoclonus. Mov Disord 2007 0.75
107 Preface. Handb Clin Neurol 2007 0.75
108 Effect of late initiation of levodopa treatment in patients with long-standing Parkinson's disease. Clin Neuropharmacol 2003 0.75
109 Long-term Parkinson's disease--time for optimism. Biomed Pharmacother 2008 0.75
110 Longitudinal MRI and MRSI characterization of the quinolinic acid rat model for excitotoxicity: peculiar apparent diffusion coefficients and recovery of N-acetyl aspartate levels. NMR Biomed 2010 0.75
111 MELAS syndrome associated with both A3243G-tRNALeu mutation and multiple mitochondrial DNA deletions. J Neurol Sci 2010 0.75
112 Toxic causes of parkinsonism. Handb Clin Neurol 2007 0.75
113 Sensory symptoms in Parkinson's disease. Handb Clin Neurol 2007 0.75